The biochemistry of drug metabolism - An introduction Part 1. Principles and overview

Chemistry and Biodiversity

Volumn 3, Issue 10, 2006, Pages 1053-1101

  Testa, Bernard ^a   Krämer, Stefanie D ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL; AGRICULTURAL CHEMICAL; AMINO ACID; ANABOLIC AGENT; CALCIUM; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHLORDANE; CHLORIDE; CHLORPHENOTANE; DIMETHYL SULFOXIDE; FATTY ACID; FOOD ADDITIVE; GROWTH HORMONE; HYDROLASE; INSULIN; ISOMERASE; LEVODOPA; LIGASE; LIPID; LYASE; MINERAL; OXIDOREDUCTASE; POLYCHLORINATED BIPHENYL DERIVATIVE; PROPRANOLOL; PSYCHEDELIC AGENT; SODIUM; TRANSFERASE; UNINDEXED DRUG; XENOBIOTIC AGENT;

BIOCHEMISTRY; BIOSYNTHESIS; CATABOLISM; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; LIPOPHILICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PHARMACODYNAMICS; POLLUTANT; PROTECTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TOXICITY;

ANIMALS; BIOTRANSFORMATION; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION; XENOBIOTICS;

EID: 33750632169     PISSN: 16121872     EISSN: 16121880     Source Type: Journal    
DOI: 10.1002/cbdv.200690111     Document Type: Review

References (122)

1. A. Conti, M. H. Bickel, 'History of drug metabolism: discoveries of the major pathways in the 19th century', Drug Metab. Rev. 1977, 6, 1-50
2. C. Bachmann, M. H. Bickel, 'History of drug metabolism: the first half of the 20th century', Drug Metab. Rev. 1986, 16, 185-253.
3. International Society for the Study of Xenobiotics, www.issx.org.
4. R. T Williams, 'Detoxication Mechanisms', Chapman & Hall, London, 1947.
5. R. T Williams, 'Detoxication Mechanisms', 2nd edn., Chapman & Hall, London, 1959.
6. B. Testa, P. Jenner, 'Drug Metabolism: Chemical and Biochemical Aspects', Dekker, New York, 1976.
7. B. Testa, P. Jenner, 'The coming of age of drug metabolism', Curr. Contents Life Sci. 1990, 33, 17.
8. 'Concepts in Drug Metabolism', Eds. R Jenner, B. Testa, Dekker, New York, 1980 and 1981, Part A and Part B.
9. 'Drug Metabolism - from Molecules to Man', Eds. D. J. Benford, J. W. Bridges, G. G. Gibson, Taylor & Francis, London, 1987.
10. 'Conjugation Reactions in Drug Metabolism', Ed. G. J. Mulder, Taylor & Francis, London, 1990.
11. 'Pharmacokinetics of Drugs', Eds. P. G. Welling, L. P. Balant, Springer, Heidelberg, 1994.
12. 'Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity', Ed. F C. Kauffman, Springer Verlag, Berlin, 1994.
13. 'Conjugation-Dependent Carcinogenicity and Toxicity of Foreign Compounds', Eds. M. W. Anders, W. Dekant, Academic Press, San Diego, 1994.
14. 'Cytochrome P450. Structure, Mechanism, and Biochemistry', 2nd edn., Ed. P. R. Ortiz de Montellano, Plenum Press, New York, 1996.
15. 'Handbook of Drug Metabolism', Ed. T. F. Woolf, Dekker, New York, 1999.
16. 'Drug Metabolism: Databases and High-Throughput Testing during Drug Design and Development', Ed. P. W. Erhardt, International Union of Pure and Applied Chemistry and Blackwell Science, London, 1999.
17. 'Enzyme Systems that Metabolise Drugs and Other Xenobiotics', Ed. C. Ioannides, John Wiley & Sons, Chichester, 2002.
18. 'Drug-Drug Interactions', Ed. A. D. Rodrigues, Dekker, New York, 2002.
19. 'Handbook of Drug-Nutrient Interactions', Eds. J. Boullata, V. T. Armenti, Humana Press, Totowa, 2004.
20. 'Drug Metabolism and Transport', Ed. L. H. Lash, Humana Press, Totowa, 2005.
21. 'Cytochrome P450 Protocols', Eds. I. R. Phillips, E. A. Shephard, Humana Press, Totowa, 2006.
22. A. Albert, 'Selective Toxicity', Chapman & Hall, London, 1985.
23. A. Albert, 'Xenobiosis', Chapman & Hall, London, 1987.
24. J. A. Timbrell, 'Principles of Biochemical Toxicology', 2nd edn., Taylor & Francis, London, 1991.
25. R. B. Silverman, 'The Organic Chemistry of Drug Design and Drug Action', Academic Press, San Diego, 1992.
26. B. Testa, 'The Metabolism of Drugs and Other Xenobiotics - Biochemistry of Redox Reactions', Academic Press, London, 1995.
27. W. N. Aldridge, 'Mechanisms and Concepts in Toxicology', Taylor & Francis, London, 1996.
28. G. G. Gibson, P. Skett, 'Introduction to Drug Metabolism', 3rd edn., Nelson Thornes, Cheltenham UK, 2001.
29. B. Testa, J. M. Mayer, 'Hydrolysis in Drug and Prodrug Metabolism - Chemistry, Biochemistry, and Enzymology', Verlag Helvetica Chimica Acta, Zurich, and Wiley-VCH, Weinheim, 2003.
30. F. J. Di Carlo, 'Metabolism, pharmacokinetics, and toxicokinetics defined', Drug Metab. Rev. 1982, 13, 1-4.
31. B. Testa, W. Soine, 'Principles of drug metabolism', in 'Burger's Medicinal Chemistry and Drug Discovery', 6th edn., Vol. 2, Ed. D. J. Abraham, Wiley-Interscience, Hoboken, 2003, p. 431-498.
32. A. Albert, 'The behaviour of foreign substances in the human body', Trends Pharmacol. Sci. 1987, 8, 258-261.
33. P. Jenner, B. Testa, F. J. Di Carlo, 'Xenobiotic and endobiotic metabolizing enzymes: an overstretched discrimination?', Trends Pharmacol. Sci. 1981, 2, 135-137.
34. W. B. Jakoby, D. M. Ziegler, 'The enzymes of detoxication', J. Biol. Chem. 1990, 265, 20715-20718.
35. D. W. Nebert, 'Proposed role of drug-metabolizing enzymes: Regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions', Mol. Endocrinol. 1991, 5, 1203-1214.
36. F. J. Gonzalez, D. W. Nebert, 'Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation', Trends Genet. 1990, 6, 182-186.
37. B. N. Ames, M. Profet, 'Nature's pesticides', Nat. Toxins 1992, 1, 2-3.
38. W. R. Jondorf, 'Drug metabolism and drug toxicity: Some evolutionary considerations', in 'Concepts in Drug Metabolism', Part B, Eds. P. Jenner, B. Testa, Dekker, New York, 1981, p. 305-376.
39. J. R. Gillette, 'The use of theoretical pharmacokinetic concepts in studies of the mechanisms of formation of chemically reactive metabolites in vitro and in vivo', Drug Metab. Rev. 1983, 14, 9-33.
40. T. J. Monks, S. S. Lau, 'Reactive intermediates and their toxicological significance', Toxicology 1988, 52, 1-54.
41. B. Testa, 'Pharmacokinetic and pharmacodynamic events: can they always be distinguished?', Trends Pharmacol. Sci. 1987, 8, 381-383.
42. 'ADME-Tox: The Fate of Drugs in the Body, Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry, 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
43. B. Testa, P. Jenner, 'Novel metabolites produced by functionalization reactions: Chemistry and toxicology', Drug Metab. Rev. 1978, 7, 325-369.
44. J. Caldwell, 'Conjugation reactions in foreign-compound metabolism: definition, consequences, and species variations', Drug Metab. Rev. 1982, 13, 745-777.
45. B. Testa, 'Nonenzymatic contributions to xenobiotic metabolism', Drug Metab. Rev. 1982, 13, 25-50.
46. T. Walle, U. K. Walle, L. S. Olanoff, 'Quantitative account of propranolol metabolism in urine of normal man', Drug Metab. Dispos. 1985, 13, 204-209.
47. B. Testa, P. Jenner, 'The concept of regioselectivity in drug metabolism', J. Pharm. Pharmacol. 1976, 28, 731-744.
48. 'Enzyme Nomenclature', Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), www.chem.qmul.ac.uk/iubmb/ enzyme.
49. T. Rodgers, D. Leahy, M. Rowland, 'Tissue distribution of basic drugs: Accounting for enantiomeric, compound and regional differences amongst β-blocking drugs in rat', J. Pharm. Sci. 2005, 94, 1237-1248
50. L. Z. Benet, B. Y. T. Perotti, L. Hardy, 'Drug absorption, distribution, and elimination', in 'Burger's Medicinal Chemistry and Drug Discovery', 6th edn., Vol. 2, Ed. D. J. Abraham, Wiley-Interscience, Hoboken, 2003, p. 633-647
51. B. Fichtl, A. von Nieciecki, K. Walter, 'Tissue binding versus plasma binding of drugs: General principles and pharmacokinetic consequences', in 'Advances in Drug Research', Vol. 20, Ed. B. Testa, Academic Press, London, 1991, p. 117-166.
52. P. J. McNamara, M. Abbassi, 'Neonatal exposure to drugs in breast milk', Pharm. Res. 2004, 21, 555-566.
53. I. Mahmood, 'Interspecies scaling of biliary excreted drugs: A comparison of several methods', J. Pharm. Sci. 2005, 94, 883-892.
54. A. E. Cribb, M. Peyton, S. Muruganandan, 'The endoplasmic reticulum in xenobiotic toxicity', Drug Metab. Rev. 2005, 37, 405-442.
55. S. A. Robert, 'High-throughput screening approaches for investigating drug metabolism and pharmacokinetics', Xenobiotics 2001, 31, 557-589.
56. + channel blockade: Current knowledge and strategies for the early prediction during drug development', Med. Res. Rev. 2005, 25, 133-166.
57. W. J. Watkins, T. E. Renau, 'Antifungal agents', in 'Burger's Medicinal Chemistry and Drug Discovery', 6th edn., Vol. 5, Ed. D. J. Abraham, Wiley-Interscience, Hoboken, 2003, p. 981-918.
58. M. Strolin Benedetti, M. Bani, 'Metabolism-based drug interactions involving oral azole antifungals in humans', Drug Metab. Rev. 1999, 31, 665-717.
59. D. E. Drayer, 'Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations', Drugs 1982, 24, 519-542.
60. A. Fura, Y. Z. Shu, M. Zhu, R. L. Hanson, V. Roongta, W. G. Humphreys, 'Discovering drugs though biological transformation: Role of pharmacologically active metabolites in drug discovery', J. Med. Chem. 2004, 47, 4339-4351.
61. P. Ettmayer, G. Amidon, B. Clement, B. Testa, 'Lessons learned from marketed and investigational prodrugs', J. Med. Chem. 2004, 47, 2393-2404.
62. B. Testa, 'Prodrug research: Futile or fertile?', Biochem. Pharmacol. 2004, 68, 2097-2106.
63. D. P. Williams, D. J. Naisbitt, 'Toxicophores: Groups and metabolic routes associated with increased safety risk', Curr. Opin. Drug Discov. Dev. 2002, 5, 104-115.
64. A. S. Kalgutkar, I. Gardner, R. S. Obach, C. L. Schaffer, E. Callegari, K. R. Henne, A. E. Mutlib, D. K. Dalvie, J. S. Lee, Y. Nakai, J. P. O'Donnell, J. Boer, S. P. Harriman, 'A comprehensive listing of bioactivation pathways of organic functional groups', Curr. Drug Metab. 2005, 6, 161-225.
65. M. H. Bickel, 'Factors affecting the storage of drugs and other xenobiotics in adipose tissue', in 'Advances in Drug Research', Vol. 25, Eds. B. Testa, U. A. Meyer, Academic Press, London, 1994, p. 56-86.
66. E. Stokstad, 'Pollution gets personal', Science 2004, 304, 1892-1894
67. P. Webster, 'Exposure to flame retardants on the rise', Science 2004, 304, 1730.
68. K. R. Scott, 'Anticonvulsants', in 'Burger's Medicinal Chemistry and Drug Discovery', 6th edn., Vol. 6, Ed. D. J. Abraham, Wiley-Interscience, Hoboken, 2003, p. 263-328.
69. J. Lazarou, B. H. Pomeranz, P. N. Corey, 'Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies', J. Am. Med. Assoc. 1998, 279, 1200-1205.
70. R. Bullingham, 'Pharmacogenomics: how gene variants can ruin good drugs', Curr. Drug Discov. 2001 (March), 17-20.
71. C. Esser, 'Immunotoxicology', in 'ADME-Tox: The Fate of Drugs in the Body, Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
72. H. van de Waterbeemd, B. Testa, 'The Why and How of ADMET Research', in 'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press
73. 'Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies', Eds. B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy, Verlag Helvetica Chimica Acta, Zurich, and Wiley-VCH, Weinheim, 2001
74. 'Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies', Eds. B. Testa, S. Krämer, H. Wunderli-Allenspach, G. Folkers, Verlag Helvetica Chimica Acta, Zurich, and Wiley-VCH, Weinheim, 2006.
75. D. A. Smith, E. F. Schmid, 'Drug withdrawals and the lessons within', Curr. Opin. Drug Discov. Dev. 2006, 9, 38-46.
76. D. A. Smith, E. F. Schmid, B. Jones, 'Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery?', Clin. Pharmacokin. 2002, 41, 1005-1019.
77. T. N. Thompson, 'Optimization of metabolic stability as a goal of modern drug design', Med. Res. Rev. 2001, 21, 412-449.
78. C. Helma, 'In silico predictive toxicology: The state-of-the-art and strategies to predict human health effects', Curr. Opin. Drug Discov. Dev. 2005, 8, 27-31.
79. N. Greene, 'Computational models to predict toxicity', in 'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
80. M. Cronin, 'In silico models to predict passage through the skin and other biological barriers', in 'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
81. Y. Parmentier, M. J. Bossant, M. Bertrand, B. Walther, 'In vitro studies of drug metabolism', in 'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
82. I. A. M. De Graaf, C. E. Van Meijeren, F. Pektas, H. J. Koster, 'Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism', Drug Metab. Dispos 2002, 30, 1129-1136.
83. H. C. Rawden, D. J. Carlile, A. Tindall, D. Hallifax, A. Galetin, K. Ito, J. B. Houston, 'Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans', Xenobiotica 2005, 35, 603-625.
84. R. J. Weaver, 'Assessment of drug-drug interactions: concepts and approaches', Xenobiotica 2001, 31, 499-538.
85. D. C. Evans, D. P. Hartley, R. Evers, 'Chapter 31. Enzyme Induction - Mechanisms, Assays, and Relevance to Drug Discovery and Development', Annu. Rep. Med. Chem. 2003, 38, 315-331.
86. D. A. Smith, 'Induction and drug development', Eur. J. Pharm. Sci. 2000, 11, 185-189.
87. C. Yao, R. H. Levy, 'Inhibition-based metabolic drug-drug interactions: predictions from in vitro data', J. Pharm. Sci. 2002, 91, 1923-1935.
88. B. Oesch-Bartlomowicz, F. Oesch, 'Mechanisms of toxification and detoxification which challenge drug candidates and drugs', in'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
89. M. Ingelman-Sundberg, 'Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development', Drug Metab. Dispos. 2001, 29, 570-573.
90. H. Reiser, 'Pharmacogenetics and drug development', Annu. Rep. Med. Chem. 2005, 40, 414-427.
91. B. Testa, 'Prodrug objectives and design', in 'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
92. B. Testa, A.-L. Balmat, A. Long, 'Predicting drug metabolism - Concepts and challenges', Pure Appl. Chem. 2004, 76, 907-914.
93. D. R. Hawkins, 'Comprehensive expert systems to predict drug metabolism', in 'ADME-Tox: The Fate of Drugs in the Body', Eds, B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
94. W. F. Trager, 'Principles of drug metabolism 1: Redox reactions', in 'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
95. B. Testa, 'Principles of drug metabolism 2: Hydrolysis and conjugation reactions', in 'ADME-Tox: The Fate of Drugs in the Body', Eds. B. Testa, H. van de Waterbeemd, in 'Comprehensive Medicinal Chemistry', 2nd edn., Eds. D. J. Triggle, J. Taylor, Elsevier, Oxford, Vol. 5, in press.
96. Y. Giroud, P. A. Carrupt, A. Pagliara, B. Testa, R. G. Dickinson, 'Intrinsic and intramolecular lipophilicity effects in O-glucuronides', Helv. Chim. Acta 1998, 81, 330-341.
97. R. DeWitte, 'Overcoming the quantity-quality trade-off in preclinical profiling', DrugPlus Intern. 2006 (April/May), 16-19.
98. K. R Persson, S. Ekehed, C. Otter, E. S. M. Lutz, J. McPheat, C. M. Masimirembwa, T. B. Andersson, 'Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome P450 induction potential of drugs in vivo in humans', Pharm. Res. 2006, 23, 56-69.
99. D. M. Cross, M. K. Bayliss, 'A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development', Drug Metab. Rev. 2000, 32, 219-240.
100. D. S. Wishart, 'Bioinformatics in drug development and assessment', Drug Metab. Rev. 2005, 37, 279-310.
101. B. Testa, G. Cruciani, 'Structure-metabolism relations, and the challenge of predicting biotransformation', in 'Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies', Eds. B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy, Verlag Helvetica Chimica Acta, Zurich, and Wiley-VCH, Weinheim, 2001, p. 65-84.
102. B. Testa, P. Crivori, M. Reist, R A. Carrupt, 'The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples', Perspect. Drug Discov. Des. 2000, 19, 179-211.
103. C. Hansch, S. B. Mekapati, A. Kurup, R. P. Verma, 'QSAR of cytochrome P450', Drug Metab. Rev. 2004, 36, 105-156.
104. J. P. Jones, M. Mysinger, K. R. Korzekwa, 'Computational models for cytochrome P450: A predictive electronic model for aromatic oxidation and hydrogen atom abstraction', Drug Metab. Dispos. 2002, 30, 7-12.
105. D. L. Harris, 'In silico predictive metabolism: A structural/electronic filter method', Curr. Opin. Drug Discov. Dev. 2004, 7, 43-48.
106. L. E. Korhonen, M. Rahnasto, N. J. Mähönen, C. Wittekindt, A. Poso, R. O. Juvonen, H. Raunio, 'Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors', J. Med. Chem. 2005, 48, 3808-3815.
107. M. J. Sorich, J. O. Miners, R. A. McKinnon, P. A. Smith, 'Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity', Mol. Pharmacol. 2004, 65, 301-308.
108. D. F. V. Lewis, 'Molecular modeling of human cytochrome P450-substrate interactions', Drug Metab. Rev. 2002, 34, 55-67.
109. D. F. V. Lewis,'Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure', Xenobiotica 2002, 32, 305-323.
110. M. J. de Groot, A. A. Alex, B. C. Jones, 'Development of a combined protein and pharmacophore model for cytochrome P450 2C9', J. Med. Chem. 2002, 45, 1983-1993.
111. C. de Graaf, N. P. E. Vermeulen, K. A. Feenstra, 'Cytochrome P450 in silico: An integrative modeling approach', J. Med. Chem. 2005, 48, 2725-2755.
112. L. Afzelius, I. Zamora, C. M. Misimirembwa, A. Karlén, T. B. Andersson, S. Mecucci, M. Baroni, G. Cruciani, 'Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors', J. Med. Chem 2004, 47, 907-914
113. G. Cruciani, E. Carosati, B. DeBoeck, K. Ethirajulu, C. Mackie, T. Howe, R. Vianello, 'MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist', J. Med. Chem. 2005, 48, 6970-6979; www.moldiscovery.com.
114. S. Ekins, S. Andreyev, A. Ryabov, E. Kirillov, E. A. Rakhmatulin, A. Bugrim, T. Nikolskaya, 'Computational prediction of human drug metabolism', Exp. Opin. Drug Metab. Toxicol. 2005, 1, 303-324; www.geneco.com.
115. MDL Information Systems Inc., www.mdl.com.
116. Accelyrs Ltd., www.accelrys.com.
117. 'Biotransformations: A Survey of the Biotransformations of Drugs and Chemicals in Animals', Vols. 1-7, Ed. D. R. Hawkins, Royal Society of Chemistry, Cambridge, UK, 1988-1996.
118. S. A. Kulkarni, J. Zhu, S. Blechinger, 'In silico techniques for the study and prediction of xenobiotic metabolism: A review', Xenobiotica 2005, 35, 955-973.
119. P. Darvas, S. Marokházi, P. Kormos, G. Kulkarni, H. Kalász, A. Papp, 'MetabolExpert: Its use in metabolism research and in combinatorial chemistry', in 'Drug Metabolism: Databases and High-Throughput Testing During Drug Design and Development', Ed. P. W. Erhardt, International Union of Pure and Applied Chemistry and Blackwell Science, London, 1999, p. 237-270; www.compudrug.com.
120. G. Klopman, M. Tu, 'META: A program for the prediction of the products of mammal metabolism of xenobiotics', in 'Drug Metabolism: Databases and High-Throughput Testing During Drug Design and Development', Ed. P. W Erhardt, International Union of Pure and Applied Chemistry and Blackwell Science, London, 1999, p. 271-276; www.multicase.com.
121. J. J. Langowski, A. Long, 'Computer systems for the prediction of xenobiotic metabolism', Adv. Drug Delivery Rev. 2002, 54, 407-415
122. B. Testa, A. L. Balmat, A. Long, P. Judson, 'Predicting drug metabolism - An evaluation of the expert system METEOR', Chem. Biodiv. 2005, 2, 872-885; www.lhasalimited.org.